Tag: gastric cancer drugs market.

  • Comprehensive Gastric Cancer Drugs Market Analysis 2024: Size, Share, And Key Trends

    Comprehensive Gastric Cancer Drugs Market Analysis 2024: Size, Share, And Key Trends

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    What Growth Rate Can Be Expected in the Gastric Cancer Drugs Market from 2024 Through 2033?

    In the recent past, the market size for drugs related to gastric cancer has seen a significant growth. It is projected to rise from $3.91 billion in 2023 to $4.41 billion in 2024, showing a compound annual growth rate (CAGR) of 12.8%. The expansion experienced in the historic period is credited to the rise in expenditure for pharmaceutical research & development, increased spend on healthcare, robust economic growth in rising markets, and swift increase in the aged population.

    In the coming years, the market size for gastric cancer drugs is set to undergo swift expansion. By 2028, it is predicted to reach $6.92 billion, growing at a compound annual growth rate (CAGR) of 11.9%. The growth during the projected period is down to a rise in the number of gastric cancer cases, a robust drugs pipeline, an escalation in acquisitions and alliances for the development of drugs, an increase in healthcare spending, a burgeoning potential in emerging economies, a growing elderly population and revised FDA guidelines to aid biologics drug development. Key trends for the period forecast include strategic collaborations and contracts to expand product ranges, collaborating and forming partnerships with other companies or government agencies to speed up new drug development, an increase in pipeline studies within gastric cancer drug research, investments in AI solutions to decrease R&D expenditures, progression of next-gen biologics to boost revenue and market share, and application of CRISPR-Cas9 technology in the development of new drugs or for improved outcomes in gastric cancer treatment.

    Claim Your Free Sample of the Global Gastric Cancer Drugs Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

    What Dynamics Are Shaping the Growth of the gastric cancer drugs Market?

    Increase in obesity and smoking population has escalated the count of individuals affected by gastric cancer. Adopting an unhealthy diet and the usage of tobacco bolsters the chances of developing stomach cancer. The American Institute for Cancer Research’s 2020 predictions suggests approximately 27,600 instances of stomach cancer anticipated to be diagnosed, including 16,980 men and 10,620 women. This rising number of gastric cancer cases promotes growth in the market for gastric cancer drugs.

    What Are the Essential Segments of the Gastric Cancer Drugs Market?

    1) By Type: Imatinib, Trastuzumab, Other Types

    2) By Route of Administration: Oral, Parenteral

    3) By End User: Hospitals, Clinics, Cancer Specialty Centers

    What Are the Defining Trends in the Evolving Gastric Cancer Drugs Market?

    Numerous organizations are turning to blended therapies to treat gastric cancer. These mixed strategies enhance patient care by using two or more medications to target a single disease. For example, AstraZeneca PLC., a pharmaceutical and biotechnology firm from the UK, revealed in January 2021, that the Food and Drug Administration (FDA) in the US had given their approval for the use of Enhertu (trastuzumab deruxtecan) for adult patients with advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinomas who have previously been treated with a trastuzumab-based regimen. This combination of trastuzumab along with fluoropyrimidine- and platinum-based chemotherapy is given to patients dealing with developed gastric cancer or GEJ adenocarcinoma.

    Order Now for Fast Delivery of Your Gastric Cancer Drugs Market Report!

    https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

    Which Regions Are Emerging as Leaders in the Gastric Cancer Drugs Market?

    North America was the largest region in the gastric cancer drugs market in 2023. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    The Gastric Cancer Drugs Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the gastric cancer drugs market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Gastric Cancer Drugs Market Include

    1. Gastric Cancer Drugs Market Executive Summary

    2. Gastric Cancer Drugs Market Segments

    3. Gastric Cancer Drugs Market Size And Template Market Growth Rate

    4. Key Gastric Cancer Drugs Market Trends

    5. Major Gastric Cancer Drugs Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Gastric Cancer Drugs Market

    26. Top Gastric Cancer Drugs Companies

    27. Gastric Cancer Drugs Market Opportunities And Strategies

    28. Gastric Cancer Drugs Market, Conclusions And Recommendations

    29. Appendix

    Discover Related Reports by The Business Research Company:

    Diuretics Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report

    Genito-Urinary Drugs Global Market Report 2022

    https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report

    Musculoskeletal Disorders Drugs Global Market Report 2022

    https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Growth Trajectory Of The Gastric Cancer Drugs Market 2024-2033

    Growth Trajectory Of The Gastric Cancer Drugs Market 2024-2033

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

    Introduction

    The gastric cancer drugs market has witnessed significant growth in recent years, driven by factors such as rising incidence rates, advancements in pharmaceutical research, and strategic collaborations within the industry. Understanding the historical growth drivers and emerging trends in this market provides valuable insights into its trajectory and potential opportunities for stakeholders.

    Historical Growth Drivers

    • Increase in pharmaceutical R&D expenditure
    • Growing healthcare expenditure
    • Economic growth in emerging markets
    • Rapid growth in the elderly population

    Current Market Dynamics

    Rising Gastric Cancer Cases Fuel Growth

    • Obesity and smoking contributing to gastric cancer prevalence
    • Unhealthy diet and tobacco consumption as risk factors
    • Estimates from the American Institute for Cancer Research highlighting the increasing diagnosis of stomach cancer

    View More On The Gastric Cancer Drugs Market Report 2024 – https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

    Strategic Collaborations and Acquisitions

    Bristol-Myers Squibb’s Opdivo (Nivolumab) FDA Approval

    • Introduction of innovative immunotherapy drug Opdivo for gastric cancer treatment
    • FDA approval for advanced or metastatic gastric cancer
    • Opdivo’s role as an immune checkpoint inhibitor in cancer therapy

    Amgen’s Acquisition of Five Prime Therapeutics

    • Acquisition to enhance Amgen’s oncology product portfolio
    • Expansion of assets in gastric cancer treatment and monoclonal antibody manufacturing
    • Five Prime Therapeutics’ expertise in immuno-oncology protein therapeutics

    Forecasted Growth Trends

    Increase in Gastric Cancer Incidence Rates

    • Growing prevalence contributing to market expansion
    • Strong pipeline of drugs to address rising incidence rates
    • Focus on developing targeted therapies for gastric cancer treatment

    Strategic Collaborations and Agreements

    • Broadening product portfolios through partnerships
    • Collaborating with government bodies to advance research initiatives
    • Expanding pipeline studies for the development of gastric cancer drugs

    Investment in Technological Advancements

    • Utilizing AI solutions to reduce R&D costs and accelerate drug development
    • Development of next-generation biologics for enhanced efficacy
    • Integration of CRISPR-cas9 technology in drug development processes

    Market Segmentation

    1) By Type:

    • Imatinib
    • Trastuzumab
    • Other Types

    2) By Route of Administration:

    • Oral
    • Parenteral

    3) By End User:

    • Hospitals
    • Clinics
    • Cancer Specialty Centers

    Regional Insights

    • North America: Largest region in 2023
    • Middle East: Expected to be the largest growing region in the forecast period

    Conclusion

    In conclusion, the gastric cancer drugs market is poised for rapid growth, driven by rising incidence rates, advancements in pharmaceutical research, and strategic collaborations within the industry. With a focus on developing innovative therapies and expanding market presence through strategic acquisitions and partnerships, stakeholders are well-positioned to capitalize on emerging opportunities and make significant contributions to the field of oncology.

    Request A Sample Of The Global Gastric Cancer Drugs Market Report 2024:
    https://www.thebusinessresearchcompany.com/sample_request?id=2603&type=smp